Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 451.77M | 354.26M | 325.72M | 264.86M | 298.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 451.77M | 354.26M | 325.72M | 264.86M | 298.01M |
| Cost of Revenue | 110.67M | 72.49M | 46.36M | 51.63M | 62.50M |
| Gross Profit | 341.10M | 281.77M | 279.36M | 213.23M | 235.51M |
| SG&A Expenses | 63.33M | 46.09M | 41.61M | 42.36M | 42.25M |
| Depreciation & Amortization | 23.38M | 17.76M | 17.76M | 17.76M | 17.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.37M | 136.34M | 123.28M | 123.33M | 122.51M |
| Operating Income | 254.40M | 217.92M | 202.44M | 141.54M | 175.50M |
| Income Before Tax | -100.85M | 218.96M | 204.94M | 143.83M | 178.21M |
| Income Tax Expenses | 40.74M | 43.73M | 39.78M | 25.73M | 41.20M |
| Earnings from Continuing Operations | -141.59M | 175.23M | 165.16M | 118.10M | 137.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.59M | 175.23M | 165.16M | 118.10M | 137.01M |
| EBIT | 254.40M | 217.92M | 202.44M | 141.54M | 175.50M |
| EBITDA | 279.08M | 236.84M | 221.44M | 160.48M | 194.52M |
| EPS Basic | -1.20 | 1.49 | 1.36 | 0.96 | 1.08 |
| Normalized Basic EPS | 1.34 | 1.17 | 1.06 | 0.72 | 0.87 |
| EPS Diluted | -1.20 | 1.43 | 1.33 | 0.93 | 1.06 |
| Normalized Diluted EPS | 1.34 | 1.12 | 1.03 | 0.70 | 0.85 |
| Average Basic Shares Outstanding | 117.67M | 117.22M | 121.34M | 123.22M | 126.41M |
| Average Diluted Shares Outstanding | 117.67M | 122.33M | 124.16M | 126.64M | 128.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |